Abnormality

ScreenPoint Medical Showcases Transpara® Breast AI Designed to Improve Cancer Detection and Support Single Reader Screening at ECR

Retrieved on: 
Wednesday, February 21, 2024

VIENNA, Feb. 21, 2024 /PRNewswire/ -- ScreenPoint Medical is showcasing its industry leading Transpara Breast AI at the 2024 European Congress of Radiology (ECR) meeting, February 28-March 3, 2024 (Booth #AI-31 in Expo Hall X1). Transpara provides radiologists with a 'second pair' of eyes to help detect cancers earlier and reduce recall rates.

Key Points: 
  • Transpara continues to deliver proven clinical and workflow benefits in mammography screening in global practice and clinical research.
  • AI-supported screening resulted in significant and substantial improvements compared to double reading without AI.
  • This presentation can be seen is: "Is it worth reading low-risk breast cancer screening mammograms as determined by an artificial intelligence (AI) system?
  • An informed review of 120 interval cancer cases with high AI scores in breast screen Norway (RPS-2405, ACV Research Stage 1, March 3, 11.30am).

ScreenPoint Medical Showcases Transpara® Breast AI Designed to Improve Cancer Detection and Support Single Reader Screening at ECR

Retrieved on: 
Wednesday, February 21, 2024

VIENNA, Feb. 21, 2024 /PRNewswire/ -- ScreenPoint Medical is showcasing its industry leading Transpara Breast AI at the 2024 European Congress of Radiology (ECR) meeting, February 28-March 3, 2024 (Booth #AI-31 in Expo Hall X1). Transpara provides radiologists with a 'second pair' of eyes to help detect cancers earlier and reduce recall rates.

Key Points: 
  • Transpara continues to deliver proven clinical and workflow benefits in mammography screening in global practice and clinical research.
  • AI-supported screening resulted in significant and substantial improvements compared to double reading without AI.
  • This presentation can be seen is: "Is it worth reading low-risk breast cancer screening mammograms as determined by an artificial intelligence (AI) system?
  • An informed review of 120 interval cancer cases with high AI scores in breast screen Norway (RPS-2405, ACV Research Stage 1, March 3, 11.30am).

Dave Chappelle has built a reputation for ‘punching down’ on trans people – and now he’s targeting disabled people

Retrieved on: 
Wednesday, January 17, 2024

Chappelle recalls being “very disappointed” at having to pretend to be speaking to Kaufman, when he could clearly see it was Carrey.

Key Points: 
  • Chappelle recalls being “very disappointed” at having to pretend to be speaking to Kaufman, when he could clearly see it was Carrey.
  • “That’s how trans people make me feel.” Whether or not non-transgender people find it funny, it is a joke that stabs at the fundamental insecurity of being trans.
  • It takes the stance of biological essentialism: that people have innate and intractable traits by virtue of their biology.

Mirroring prejudice

  • Chappelle is either unaware or just doesn’t care that the term is decades out of date.
  • It slips into mockery when, bereft of understanding, it does nothing more than mirror prejudice.
  • He says:
    there’s probably a handicap in the back right now ’cause that’s where they make them sit.
  • there’s probably a handicap in the back right now ’cause that’s where they make them sit.
  • Instead, it seems he embraces being an “equal opportunity” offender who mocks disability as a defence for his long-running transgender jokes.

The impacts of mockery

  • His jokes rely on prevailing disgust about transgender bodies and increasingly politicised insistence that transgender people are not real women or men.
  • These views shared in popular culture are coming to inform anti-trans policy in healthcare, education and the justice system.
  • As the majority of the general population do not know a trans person, the media has significant influence over perceptions of trans people.
  • Throughout four Netflix specials, Chapelle has made no effort to understand the object of his jokes or the impact of his mockery on their daily lives.


The authors do not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and have disclosed no relevant affiliations beyond their academic appointment.

Newborn Screening Market Analysis Report 2023 - Global Forecast to 2030 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 16, 2024

The "Newborn Screening Market by Product Technology Application End User - Global Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Newborn Screening Market by Product Technology Application End User - Global Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global newborn screening market is projected to reach $2.49 billion by 2030, at a CAGR of 7.9% from 2023 to 2030.
  • Among products, in 2023, the consumables segment is expected to account for the largest share of the newborn screening market.
  • Among applications, in 2023, the inherited disorders segment is expected to account for the largest share of the newborn screening market.

Following Extreme Drought and Heat, SeaWorld Conservation Fund Makes Emergency Grant to Help Save Endangered Amazon River Dolphins in Brazil

Retrieved on: 
Thursday, November 30, 2023

ORLANDO, Fla., Nov. 30, 2023 /PRNewswire/ -- Following extreme drought and heat in the Brazilian Amazon rainforest, the SeaWorld Conservation Fund made an emergency grant to the Mamirauá Institute for Sustainable Development (IDSM) to support the rescue of Amazon river dolphins and mitigate the impact of the environmental emergency in and around Lake Tefé, located in the Brazilian Amazon rainforest. Amazon river dolphins, many of a striking pink color, are a unique freshwater species found only in the rivers of South America and are one of a handful of freshwater dolphin species left in the world. The IDSM is using this grant to further its efforts in recovering dolphin carcasses and gathering biological samples for analyses, with the goal of determining the cause of death. Additionally, IDSM is implementing a comprehensive rescue plan to rescue, treat and translocate healthy dolphins to a more suitable natural habitat.

Key Points: 
  • The SeaWorld Conservation Fund provides grants around the world to grassroots conservation projects that make a difference in species research, habitat protection, conservation education and animal rescue and rehabilitation.
  • To date, there have been 154 Amazon river dolphin casualties reported, including both the pink river dolphins and tucuxi dolphins.
  • The Tefé Dolphins Emergency Operation, launched by the Chico Mendes Institute for Biodiversity Conservation (ICMBio) with technical support from IDSM, monitors the Amazon river dolphins.
  • Since the beginning of the crisis, there have been 154 deceased Amazon river dolphins, with 131 pink river dolphins and 23 tucuxis.

ConcertAI's TeraRecon Adds Third Party Partner CoLumbo to its Eureka Clinical AI Platform

Retrieved on: 
Thursday, July 20, 2023

CAMBRIDGE, Mass., July 20, 2023 /PRNewswire/ -- Advanced visualization and AI leader TeraRecon, a ConcertAI company, is excited to announce that its Eureka Clinical AI platform now provides clinicians with the state-of-the-art machine learning technology for reading and analysis of lumbar spine MR scans through the addition of CoLumbo to the platform.

Key Points: 
  • "We are thrilled to be a part of the TeraRecon AI partner ecosystem and to offer our solution both on the Eureka Clinical AI platform and to all healthcare providers needing these services in the streamlined and best-in-breed ecosystem that TeraRecon offers."
  • "I am thrilled to announce our groundbreaking partnership with CoLumbo, uniting our strengths and expertise in healthcare imaging with the power of the Eureka AI Platform," said Dan McSweeney, President, TeraRecon.
  • Eureka Clinical AI is the leading AI SaaS imaging interpretation and clinical decision augmentation solution from ConcertAI's TeraRecon.
  • Learn more about the Eureka Clinical AI platform capabilities and algorithms that span across neurology, radiology, cardiology, oncology, and more: https://www.terarecon.com/artificial-intelligence .

Dr. Thomas Yarbrough Joins PetVivo Holdings, Inc. as the Senior Research Director

Retrieved on: 
Monday, June 5, 2023

He began his career developing a referral base while working in research under the esteemed Dr. Hari Reddi at the Center for Tissue Regeneration and repair at the UC Medical center.

Key Points: 
  • He began his career developing a referral base while working in research under the esteemed Dr. Hari Reddi at the Center for Tissue Regeneration and repair at the UC Medical center.
  • Throughout his career he has stayed peripherally involved in research both from the bench-top to the clinic.
  • Although varied in scope his primary research interests and passion has always involved the arena of management of osteoarthritis.
  • Colleagues that know him know he is an open skeptic very slow to follow the new trends that frequent the veterinary space.

New and Real-World Clinical Evidence Confirms ProFound AI Increases Cancer Detection without Increasing the Rate of Recalls and Reveals Critical Clues to Inform Clinical Decisions

Retrieved on: 
Thursday, April 20, 2023

(NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced new real-world research confirms ProFound AI® has been proven to increase cancer detection rates and provide vital clues for breast imagers' clinical decisions through two studies.

Key Points: 
  • (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced new real-world research confirms ProFound AI® has been proven to increase cancer detection rates and provide vital clues for breast imagers' clinical decisions through two studies.
  • One study demonstrated that ProFound AI improved radiologists' performance in detecting breast cancer and providing better accuracy, without increasing abnormal interpretation rates or the rate of recalls.
  • iCAD’s ProFound AI increased cancer detection rates and positive predictive value for cancer among abnormal interpretations (PPV1), without increasing abnormal interpretation rates across the radiologists studied.
  • Researchers concluded ProFound AI resulted in clinically relevant increases in cancer detection, without increasing the rate of recalls.

Prostate Cancer Treatment can be safely delayed, and inexpensively and accurately monitored thanks to new Artificial Intelligence

Retrieved on: 
Tuesday, March 28, 2023

Therefore, biopsies are not an effective screening tool for prostate cancer, but are a confimatory tool if utilized with imaging guidance.

Key Points: 
  • Therefore, biopsies are not an effective screening tool for prostate cancer, but are a confimatory tool if utilized with imaging guidance.
  • In conclusion, bpMRI with CAD (AI) such as ProstatID, is poised to change the Standard of Care for Prostate Cancer screening, detection and diagnosis by avoiding the costly pitfalls of current prostate cancer pathways.
  • al., Fifteen-year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer, NEJM, March 11, 2023.
  • Circulating Chromosome Conformation Signatures Significantly Enhance PSA Positive Predicting Value and Overall Accuracy for Prostate Cancer Detection.

WhaleTeq: Widespread as AEDs Are, Have These Life-Saving Machines Really Come in Handy?

Retrieved on: 
Friday, June 24, 2022

Besides, AEDs are designed for use by laypersons with very little training because of its easy operation.

Key Points: 
  • Besides, AEDs are designed for use by laypersons with very little training because of its easy operation.
  • In Japan, 2014 is the tenth anniversary of the Japanese government's opening to the public for free use of AEDs.
  • With the premise that most AEDs have been set up without regular maintenance, its availability is indeed a concern.
  • We strive to assist our clients in launching their top-quality medical devices to the market in the most efficient way.